CD34 + CD19 − CD22 + B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies

CD34 + CD19 − CD22 + B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies

Three article in this issue present preclinical data aimed at improving immunotherapeutic approaches for relapsed B- and T-cell acute lymphoblastic leukemia (T-ALL). Chimeric antigen receptor T (CAR-T) cell therapy directed against relapsed T-ALL is hampered by difficulty in identifying a target ant...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Bueno, Clara, Barrera, Susana, Bataller, Alex, Ortiz-Maldonado, Valentín, Elliot, Natalina, O'Byrne, Sorcha, Wang, Guanlin, Rovira, Montse, Gutiérrez-Agüera, Francisco, Trincado Alonso, Juan Luis, 1987, González-González, María, Morgades, Mireia, Sorigue, Marc, Bárcena, Paloma, Zanetti, S. R, Torrebadell, Montse, Vega-Garcia, Nerea, Rives, Susana, Mallo, Maria del Mar, Sole, F, Mead, Adam J, Roberts, Irene, Thongjuea, Supat, Psaila, Bethan, Juan, Manel, Delgado, Julio, Urbano Ispizua, Álvaro, Ribera, Jose-Maria, Orfao, Alberto, Roy, Anindita, Menéndez Bujan, Pablo
Format: Artikel
Sprache:eng
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Three article in this issue present preclinical data aimed at improving immunotherapeutic approaches for relapsed B- and T-cell acute lymphoblastic leukemia (T-ALL). Chimeric antigen receptor T (CAR-T) cell therapy directed against relapsed T-ALL is hampered by difficulty in identifying a target antigen that is not also expressed on healthy T cells, risking "fratricide" with T-cell aplasia and loss of the CAR-T cells. Maciocia and colleagues identify CCR9 as an antigen expressed on >85% of relapsed T-ALL and on